skip to main content

H.R. 3988 (112th): Generic Drug and Biosimilar User Fee Act of 2012

To amend the Federal Food, Drug, and Cosmetic Act to establish user-fee programs for generic drugs and biosimilars.

The bill’s titles are written by its sponsor.

Tim Murphy

Sponsor. Representative for Pennsylvania's 18th congressional district. Republican.

Read Text »
Last Updated: Feb 8, 2012
Length: 88 pages
Introduced:

Feb 8, 2012
112th Congress, 2011–2013

Status:
Enacted Via Other Measures

Provisions of this bill were incorporated into other bills which were enacted.

This bill was incorporated into:

S. 3187: Food and Drug Administration Safety and Innovation Act
Enacted — Signed by the President on Jul 9, 2012. (compare text)

History

Feb 8, 2012
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

H.R. 3988 (112th) was a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

This bill was introduced in the 112th Congress, which met from Jan 5, 2011 to Jan 3, 2013. Legislation not enacted by the end of a Congress is cleared from the books.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 3988 — 112th Congress: Generic Drug and Biosimilar User Fee Act of 2012.” www.GovTrack.us. 2012. December 18, 2017 <https://www.govtrack.us/congress/bills/112/hr3988>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.